AVEO Oncology Announces Participation at Two Upcoming Investor Conferences
AVEO Oncology (Nasdaq: AVEO) announced that CEO Michael Bailey will speak at two upcoming virtual investor conferences. The H.C. Wainwright Virtual BioConnect Conference runs from January 11 to January 14, while the B. Riley Virtual Oncology Investor Conference takes place on January 20 at 1:30 PM ET. A replay of the H.C. Wainwright presentation will be available on AVEO's website, and a live webcast of the B. Riley presentation can also be accessed there. AVEO is focused on developing therapies for cancer patients, including its lead candidate, tivozanib, for advanced renal cell carcinoma.
- None.
- None.
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences:
H.C. Wainwright Virtual BioConnect Conference
Date: Monday, January 11 – Thursday, January 14
B. Riley Virtual Oncology Investor Conference
Date: Wednesday, January 20
Time: 1:30 PM Eastern Time
A replay of the pre-recorded H.C. Wainwright presentation can be accessed on Monday, January 11, 2021 in the investors section of the Company’s website at www.aveooncology.com, and a live webcast of the B. Riley presentation can be accessed in the same section of the Company’s website. A replay of the webcasts will be archived for 30 days following the presentation date.
About AVEO Pharmaceuticals, Inc.
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO’s strategy is to focus its resources toward development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO’s lead candidate, tivozanib, is approved as FOTIVDA® in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced renal cell carcinoma. Tivozanib is being studied in the TIVO-3 trial, which is supporting a regulatory submission of tivozanib in the U.S. seeking marketing approval as a treatment for relapsed or refractory renal cell carcinoma. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF mAb) in head and neck cancer, acute myeloid leukemia and pancreatic cancer and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab in head and neck cancer. AVEO’s earlier-stage pipeline includes several monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb), AV-380 (anti-GDF15 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion as a foundation for innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release
View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005199/en/
FAQ
What are the dates for the H.C. Wainwright Virtual BioConnect Conference for AVEO?
When will the B. Riley Virtual Oncology Investor Conference take place for AVEO?
How can I access the replays of AVEO's presentations?
What is the focus of AVEO's drug development?
What is the significance of the TIVO-3 trial for AVEO?
